Söndag 25 Januari | 06:06:50 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-11-12 07:00 Kvartalsrapport 2026-Q3
2026-08-19 07:00 Kvartalsrapport 2026-Q2
2026-05-14 07:00 Kvartalsrapport 2026-Q1
2026-04-23 N/A Årsstämma
2026-03-03 07:00 Bokslutskommuniké 2025
2026-01-02 - Extra Bolagsstämma 2026
2025-11-12 - Extra Bolagsstämma 2025
2025-11-12 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-15 - Kvartalsrapport 2025-Q1
2025-04-28 - X-dag ordinarie utdelning LIFE 0.00 NOK
2025-04-25 - Årsstämma
2025-02-20 - Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-01 - Split LIFE 13:1
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - Extra Bolagsstämma 2024
2024-05-08 - Kvartalsrapport 2024-Q1
2024-05-02 - X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-05-08 - X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 - Årsstämma
2022-04-21 - Bokslutskommuniké 2021
2021-09-30 - Extra Bolagsstämma 2021
2021-08-05 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 - Årsstämma
2021-04-20 - Bokslutskommuniké 2020
2020-06-26 - Årsstämma
2020-06-01 - Bokslutskommuniké 2019
2019-02-07 - Split LIFE 4:1
2018-12-11 - Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av microsensorer för diabetes. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-01-23 14:55:00

Reference is made to the stock exchange announcement by Lifecare ASA (the "Company") on 22 January 2026 regarding the final results of the rights issue of new shares in the Company, with the allocation of 160,000,000 new shares (the "Offer Shares") at the subscription price of NOK 0.50 per share, raising gross proceeds of NOK 80 million (the "Rights Issue").

Subscribers in the Rights Issue will, without cost, receive warrants in two series: (a) three (3) warrants for every four (4) Offer Shares allocated to, and paid by, them in the Rights Issue, which will be exercisable in the exercise period from 2 March 2026 to 13 March 2026 ("Warrants Series 1"); and (b) three (3) warrants for every four (4) Offer Shares allocated to, and paid by, them in the Rights Issue, which will be exercisable in the exercise period from 1 June 2026 to 12 June 2026 ("Warrants Series 2" and together with Warrants Series 1, the "Warrants").

Reference is further made to the stock exchange announcement made by the Company on 14 January 2026, regarding the subscription of Offer Shares and Warrants in the Rights Issue by Hannibal Invest AS, a company closely associated with Hans Hekland, board member of the Company. Following the allocation of Offer Shares by the Company, Hans Hekland has been allocated in total 820,261 Offer Shares, of which 200,000 Offer Shares were allocated based on exercise of subscription rights and over-subscription (as notified on 14 January 2026), and 620,261 Offer Shares were allocated pursuant to Hekland's underwriting obligation for the Rights Issue. Further, based on the number of Offer Shares allocated, Hekland has been allocated in total 1,230,392 Warrants. The allocations have been made to Hekland personally and not to Hannibal Invest AS as initially indicated.

Please see the attached PDMR form for further details.